First-generation antibody–drug conjugates (ADC) are heterogeneous mixtures that have
shown clinical benefit, but generally exhibited safety issues and a narrow therapeutic …

Antibody–drug conjugates (ADCs) consist of cytotoxic drugs covalently linked to monoclonal
antibodies directed to antigens differentially overexpressed in tumor cells. These loaded …

Antibody–drug conjugates (ADCs) are an emerging type of biotherapeutics that utilize
multiple tissue-specific antibodies combined with a range of linker designs to enable the …

Current antibody–drug conjugates (ADCs) suffer from low tissue penetration and significant
side effects, largely due to the permanent linkage and/or premature release of cytotoxic …

Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven
effective against tumors positive for HER2 amplification, but there is an unmet clinical need …

Trastuzumab deruxtecan (T‐DXd) is a HER2‐targeting antibody‐drug conjugate composed
of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor …

We improve the potency of antibody–drug conjugates (ADCs) containing the human
epidermal growth factor receptor 2 (HER2)-specific antibody pertuzumab by substantially …

Homogeneous antibody–drug conjugates (ADCs), generated by site‐specific toxin linkage,
show improved therapeutic indices with respect to traditional ADCs. However, current …

A strategy for the preparation of homogeneous antibody–drug conjugates (ADCs) containing
multiple payloads has been developed. This approach utilizes sequential unmasking of …

Antibody drug conjugates (ADCs) are an emerging class of therapeutics that consist of a
cytotoxic agent linked covalently to an antibody, which is directed toward a specific cell …